First-line treatment of metastatic renal cell carcinoma: current standard of care
Crossref DOI link: https://doi.org/10.1007/s12254-019-00550-7
Published Online: 2019-11-21
Published Print: 2019-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Marszalek, Martin
Text and Data Mining valid from 2019-11-21
Version of Record valid from 2019-11-21
Article History
Received: 8 August 2019
Accepted: 10 November 2019
First Online: 21 November 2019
Conflict of interest
: M. Marszalek serves as an advisor for Pfizer, Bristol Myer Squibb, Eusa Pharma, Eisai.